drugset / Trial / NCT02034435

Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism

NCT02034435

Phase 4 Completed 44 enrolled Vanderbilt University Medical Center
RandomizedCrossoverDouble-blindBasic science

Summary

Aim 1.Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone system impairs glycemic control via effects on insulin sensitivity and insulin secretion. Aim 2. Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone system impairs insulin secretion and insulin sensitivity via an mineralocorticoid-receptor dependent mechanism.

Timeline

Start
2013-10
Primary completion
2019-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg
Comparator Epleronone Unknown 50 mg

Indications